中医药治疗新型冠状病毒肺炎(COVID-19)的效果评价

注册号:

Registration number:

ChiCTR2000029896 

最近更新日期:

Date of Last Refreshed on:

2020-02-16 18:08:01 

注册时间:

Date of Registration:

2020-02-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

中医药治疗新型冠状病毒肺炎(COVID-19)的效果评价

Public title:

Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中医药治疗新型冠状病毒肺炎(COVID-19)的效果评价

Scientific title:

Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

仕丽 

研究负责人:

王檀 

Applicant:

Shi Li 

Study leader:

Wang Tan 

申请注册联系人电话:

Applicant telephone:

+86 15948000558

研究负责人电话:

Study leader's
telephone:

+86 13756858523

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ywonline@163.com

研究负责人电子邮件:

Study leader's E-mail:

Wangtan215@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

吉林省长春市工农大路1478号

研究负责人通讯地址:

吉林省长春市工农大路1478号

Applicant address:

1478 Gongnong Road, Changchun, Jilin, China

Study leader's address:

1478 Gongnong Road, Changchun, Jilin, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

长春中医药大学附属医院

Applicant's institution:

Affiliated Hospital of Changchun University of traditional Chinese Medicine

研究负责人所在单位:

长春中医药大学附属医院

Affiliation of the Leader:

Affiliated Hospital of Changchun University of traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

CCZYFYLL2020准字- 018

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

长春中医药大学附属医院医学伦理委员会

Name of the ethic committee:

Committee on medical ethics of Affiliated Hospital of Changchun University of traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020-01-27 00:00:00

伦理委员会联系人:

高宏伟

Contact Name of the ethic committee:

Gao Hongwei

伦理委员会联系地址:

长春中医药大学附属医院

Contact Address of the ethic committee:

Affiliated Hospital of Changchun University of traditional Chinese Medicine, 1478 Gongnong Road, Changchun, Jilin, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

长春中医药大学附属医院

Primary sponsor:

Affiliated Hospital of Changchun University of traditional Chinese Medicine

研究实施负责(组长)单位地址:

吉林省长春市工农大路1478号

Primary sponsor's address:

1478 Gongnong Road, Changchun, Jilin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

吉林

市(区县):

长春

Country:

China

Province:

Jilin

City:

Changchun

单位(医院):

长春中医药大学附属医院

具体地址:

吉林省长春市工农大路1478号

Institution
hospital:

Affiliated Hospital of Changchun University of traditional Chinese Medicine

Address:

1478 Gongnong Road

经费或物资来源:

吉林省科技厅

Source(s) of funding:

Department of Science and technology of Jilin Province

研究疾病:

新型冠状病毒肺炎  

Target disease:

novel coronavirus pneumonia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

明确结合地域特点进行中医药辨证分期治疗新型冠状病毒感染的肺炎患者临床疗效及预后,同时明确吉林省新型冠状病毒感染的肺炎患者临床特征、中医证候特点,为新型冠状病毒肺炎的诊疗提供临床参考。  

Objectives of Study:

By analyzing the clinical characteristics and TCM syndromes of pneumonia patients with new coronavirus infection diagnosed by the remote diagnosis and treatment team in our hospital, and evaluating the curative effect and prognosis of TCM syndrome differentiation and staging combined with regional characteristics, it can provide clinical reference for the diagnosis and treatment of new coronavirus pneumonia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.无法接受中医药治疗者。
2.无法获取完整诊疗信息的病例。

Exclusion criteria:

1. Unable to receive traditional Chinese medicine treatment.
2. Cases where complete diagnosis and treatment information is not available.

研究实施时间:

Study execute time:

From 2020-01-31 00:00:00 To 2020-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-01-31 00:00:00 To 2020-12-31 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

100

Group:

Case series

Sample size:

干预措施:

中医辨证处方+西医常规治疗

干预措施代码:

Intervention:

Prescription based on syndrome differentiation of TCM and Routine treatment of Western Medicine

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

吉林 

市(区县):

长春 

Country:

China

Province:

Jilin

City:

Changchun

单位(医院):

长春中医药大学附属医院 

单位级别:

三甲医院 

Institution
hospital:

Affiliated Hospital of Changchun University of traditional Chinese Medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

轻症、普通型患者转重症率

指标类型:

主要指标

Outcome:

Conversion rate of mild and common type patients to severe type

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

死亡率

指标类型:

主要指标

Outcome:

Mortality Rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床症状消失时间

指标类型:

次要指标

Outcome:

Time for clinical symptom to disappear

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床症状痊愈率

指标类型:

次要指标

Outcome:

Cure rate of clinical symptoms

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肺炎影像学吸收情况

指标类型:

次要指标

Outcome:

Imaging absorption of pneumonia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症的发生率

指标类型:

次要指标

Outcome:

The incidence of complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

重症监护时间

指标类型:

次要指标

Outcome:

Intensive Care Time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

Inhospital time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总体治疗费用

指标类型:

次要指标

Outcome:

Total cost of treatment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

联系统计师

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact the Medical Statistician

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

制定《病例报告表》,由调查员在每次中医诊疗时采集数据,内容包括以下几方面: 1、人口学资料 2、患者现病史、既往史、合并疾病史、合并用药史 3、流行病史 4、临床表现及中医症状集 5、理化检查结果 6、中医处方及用法 采用EpiDATA3.1软件建立数据库,编制数据录入程序,对录入数据进行清理、核查、锁定,撰写统计分析报告书。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Adopt to the "case report form" , which was collected and filled in real time by the investigator during the TCM consultation, the data include the following aspects: 1. Demographic Data. 2. The patient's present medical history, and past medical history, and combined medical history, and combined medical history. 3. Epidemic Medical History. 4. Clinical manifestation and TCM symptom set. 5. Physical and chemical examination. 6. TCM prescription and usage. The database is established by EPIDATA3.1 software, the data recorded into the database, and was cleaned up, checked and locked, and then statistical analysis it.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-02-16 18:08:01